All In Biotech

Drug Trial Radar · NCT02734732

Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole

Last checked: Nov 19, 2026Latest source record: May 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,800

Planned (sponsor's estimate)

Start

Apr 2015

Primary completion

Apr 2020

Study completion May 2020

Sponsor

Lead sponsor
Umeå UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine if a single dose of Ciprofloxacin and Trimethoprim/Sulfamethoxazole are equivalent for prophylaxis immediately prior to prostate biopsy, when a patient has a suspected prostate cancer.

Conditions

  • Prostate Infection

Interventions

  • Trimethoprim/SulfamethoxazoleDrug

  • CiprofloxacinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Admitted to hospital due to infectionTime frame: 14 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Ängelholm hospital

    Ängelholm, Sweden · Not yet recruiting

  • Helsingborgs Hospital

    Helsingborg, Sweden · Not yet recruiting

  • Umea University Hospital

    Umeå, Sweden · Recruiting

  • Östersunds hospital

    Östersund, Jämtland County, Sweden · Not yet recruiting

  • Sundsvalls hospital

    Sundsvall, Västernorrland County, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.